Home » Stocks » CLDX

Celldex Therapeutics, Inc. (CLDX)

Stock Price: $28.01 USD 0.93 (3.43%)
Updated Mar 1, 2021 3:23 PM EST - Market open
Market Cap 1.07B
Revenue (ttm) 4.52M
Net Income (ttm) -48.33M
Shares Out 39.28M
EPS (ttm) -2.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $28.01
Previous Close $27.08
Change ($) 0.93
Change (%) 3.43%
Day's Open 27.44
Day's Range 27.46 - 28.50
Day's Volume 337,700
52-Week Range 1.50 - 29.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 6 days ago

--Dermatological indication characterized by chronic, intensely itchy nodules; mast cell activation believed to play an important role in amplifying chronic itch and neuroinflammation-- --Pote...

GlobeNewsWire - 1 week ago

HAMPTON, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will participate in a fireside chat at the 10th Annual SVB Leerink Gl...

Seeking Alpha - 1 month ago

Celldex Therapeutics is a biopharmaceutical company focused on developing monoclonal and bispecific antibody-based therapeutics. Celldex's new pipeline is now made up of 3 Phase 1 immunotherap...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Celldex (CLDX) stock based on the movements in the options market lately.

GlobeNewsWire - 1 month ago

HAMPTON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the promotion of Freddy A. Jimenez, Esq. to Senior Vice President and General Counsel,...

The Motley Fool - 2 months ago

These stocks have made investors richer by posting explosive revenue growth or advancing significantly in high-impact programs.

Other stocks mentioned: CODX, CRDF, RVP, VXRT
The Motley Fool - 2 months ago

The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?

Other stocks mentioned: BNTX, CODX, CRDF, MCRB, MRNA, NSRGY, NVAX, TRIL, VXRT
GlobeNewsWire - 2 months ago

HAMPTON, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the first patient has been dosed in its open label clinical trial in cold contact...

GlobeNewsWire - 3 months ago

HAMPTON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in a fireside chat at the 3rd Annual Evercore ISI He...

GlobeNewsWire - 3 months ago

-- A gonist anti-CD40 mAb CDX-1140 demonstrates best-in-class potential; additional expansion cohorts initiated-- --Axl and CDX-527 programs highlighted-- HAMPTON, N.J., Nov. 09, 2020 (GLOBE N...

Zacks Investment Research - 3 months ago

Celldex (CLDX) delivered earnings and revenue surprises of -5.88% and 130.35%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

HAMPTON, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2020.

Zacks Investment Research - 3 months ago

Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 4 months ago

Here's why shares of these drugmakers seem unstoppable this year.

Other stocks mentioned: CRDF
Zacks Investment Research - 4 months ago

Celldex (CLDX) is developing its monoclonal antibody candidate CDX-0159 as a potential treatment of chronic spontaneous urticaria.

GlobeNewsWire - 4 months ago

HAMPTON, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened and the first patient has been dosed in its randomized, dou...

Seeking Alpha - 5 months ago

Why Celldex Has Been A Big Winner In 2020

Zacks Investment Research - 5 months ago

Investors need to pay close attention to Celldex Therapeutics (CLDX) stock based on the movements in the options market lately.

GlobeNewsWire - 5 months ago

HAMPTON, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in Fireside Chats at the Cantor Virtual Global He...

Zacks Investment Research - 6 months ago

Here we discuss five biotech companies recording impressive growth so far in 2020.

Other stocks mentioned: ALRN, EBS, HZNP, NVAX
GlobeNewsWire - 6 months ago

HAMPTON, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened in its open-label, Phase 1 study of CDX-527 in patients w...

Seeking Alpha - 6 months ago

Celldex Therapeutics' (CLDX) CEO Anthony Marucci on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

--Conference Call and Webcast today at 4:30pm ET-- --Conference Call and Webcast today at 4:30pm ET--

GlobeNewsWire - 6 months ago

HAMPTON, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will report second quarter 2020 financial results on Thursday, August 6, 2020 after the U.S. financi...

Zacks Investment Research - 7 months ago

Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 7 months ago

Top Ranked Momentum Stocks to Buy for July 9th

Other stocks mentioned: FCX, GAN
Zacks Investment Research - 7 months ago

As of late, it has definitely been a great time to be an investor in Celldex Therapeutics, Inc. (CLDX).

The Motley Fool - 8 months ago

Here's what pushed up shares of the highest-flying healthcare stocks.

Other stocks mentioned: IDYA, QDEL
The Motley Fool - 8 months ago

The market is reacting to large stock purchases from inside and outside the company.

GlobeNewsWire - 8 months ago

HAMPTON, N.J., June 18, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the closing of its underwritten public offering of 15...

GlobeNewsWire - 8 months ago

HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the pricing of its previously announced underwritten ...

Seeking Alpha - 8 months ago

Celldex Jumps On CDX-0159 Data

GlobeNewsWire - 8 months ago

HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced that it is proposing to offer and sell, subject to ma...

Benzinga - 8 months ago

Celldex Therapeutics Inc (NASDAQ:CLDX) was trading 3% higher from the previous closing price.

Benzinga - 8 months ago

Shares of Celldex Therapeutics Inc (NASDAQ:CLDX) moved higher by 1.5% from the previous closing price.

Zacks Investment Research - 8 months ago

Investors need to pay close attention to Celldex Therapeutics (CLDX) stock based on the movements in the options market lately.

GlobeNewsWire - 8 months ago

--Data strongly support expanding development into mast cell driven diseases----Data presented in a late-breaking session at EAACI Annual Congress 2020-- HAMPTON, N.J., June 06, 2020 (GLOBE ...

Zacks Investment Research - 9 months ago

Is (CLDX) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 10 months ago

Celldex (CLDX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

GlobeNewsWire - 11 months ago

Celldex also eligible to receive future milestone payments plus royalties Celldex also eligible to receive future milestone payments plus royalties

Zacks Investment Research - 1 year ago

Celldex (CLDX) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 1 year ago

CDX-0159 to be studied in chronic idiopathic urticaria after completing healthy volunteer study CDX-0159 to be studied in chronic idiopathic urticaria after completing healthy volunteer study

Zacks Investment Research - 1 year ago

Celldex (CLDX) reports mixed third-quarter results. Its revenues fall on reduced collaboration and contract revenues.

Zacks Investment Research - 1 year ago

Celldex (CLDX) delivered earnings and revenue surprises of 10.71% and -56.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 1 year ago

-CDX-0159 IND accepted; Phase 1 study to start by YE 2019- -CDX-527 on track for IND filing in 1H 2020-

GlobeNewsWire - 1 year ago

-Recommended and maximum tolerated dose defined as 1.5 mg/kg for further study- -Expansion cohort in head and neck squamous cell carcinoma added based on observed clinical activity- -Clinica...

GlobeNewsWire - 1 year ago

HAMPTON, N.J., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple Company drug development programs will be the subject of presentations...

GlobeNewsWire - 1 year ago

HAMPTON, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Tibor ...

Zacks Investment Research - 1 year ago

Celldex (CLDX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 year ago

Celldex (CLDX) reports mixed second-quarter results. Revenues fall on reduced collaboration and contract revenues.

About CLDX

Celldex Therapeutics, a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, which is being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in metastatic solid tumors and B cell lymphomas; CDX-3379, a monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Er... [Read more...]

Industry
Biotechnology
IPO Date
Mar 10, 2008
CEO
Anthony Marucci
Employees
127
Stock Exchange
NASDAQ
Ticker Symbol
CLDX
Full Company Profile

Financial Performance

In 2019, CLDX's revenue was $3.57 million, a decrease of -62.54% compared to the previous year's $9.54 million. Losses were -$50.88 million, -66.35% less than in 2018.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for CLDX stock is "Strong Buy." The 12-month stock price forecast is 30.67, which is an increase of 9.50% from the latest price.

Price Target
$30.67
(9.50% upside)
Analyst Consensus: Strong Buy